Trends and Safety in Revisional Bariatric Surgery in Italy

January 5, 2022 updated by: Gianfranco Silecchia, University of Roma La Sapienza

Trends and Safety in Revisional Bariatric Surgery in Italy: a High Volume Multicenter, Observational Longitudinal Study (RBST)

Background: Revisional bariatric surgery (RBS) represents a further solution for patients who experience an inadequate response following initial bariatric surgery or significant weight regain following an initial satisfactory response. Studies including the follow-up of patients with complications after RBS are still lacking. Aim: to analyze the trend, mortality, and complications at 30 days after RBS in Italy. Secondary aim: 30-day readmission rate, reoperations for any reason related to bariatric surgery. Design: longitudinal, prospective, multicenter study. Time interval: 10 months October 2021 - July 2022). Setting: 11 high-volume bariatric centers of the Italian National Health Service (SSN), university hospitals, hospitals, accredited private centers. Methods: All patients undergoing RBS from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering indications, technique, mortality, intraoperative and perioperative complications, readmission for any reason. All participating centers follow the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days. Inclusion criteria: revisional procedures; no concomitant procedure, but hiatal hernia repair; age >18<60 years; compensated comorbidities; informed consent including COVID-19 addendum; adherence to specific admission, in-hospital and follow-up protocols. Patients undergone RBS during 2016-2020 will be considered a control group. The study will not involve any modification of the usual protocols. Statistical analyze: to make qualitative quantitative comparison regarding clinical and anthropometric factors between the two study groups (2021-22; 2016-20), the z-test for two proportions and t-test (two-tailed) will be used, respectively. The significance is fixed at 0.05 and all analyzes will be performed with the SPSS v.27 software. Expected results: enroll about 500 patients to obtain information on the safety of RBS and the current trends in Italy.

Study Overview

Detailed Description

Bariatric surgery is the most effective treatment for achieving significant long-term weight reduction and resolution of comorbidities, including diabetes mellitus, arterial hypertension, sleep apnea syndrome [1]. Revisional bariatric surgery (RBS) is an option for patients who have an inadequate response after bariatric surgery for weight loss and improvement/resolution of comorbidities, or significant weight regain after a satisfactory, initial response, even with comorbidities' relapse [2,3]. All bariatric procedures are subject to failure, in different proportions, based on the type and mechanism of action and the patient's compliance to follow-up. Recent studies suggest that revision rates for sleeve gastrectomy, which is the most performed bariatric surgery in the world since 2015 [4], can be as high as 10% when patients are followed for more than 3 years and as high as 22%. after 10 years [5].

Revisional bariatric surgery is a constantly growing set of procedures. The choice of the revision procedure must consider the indication, the primary technique, and the patient's characteristics [3,6-9]. There is a lack of high-quality studies and an almost total lack of randomized data [6] on various aspects of RBS. These factors make it difficult for individual surgeons treating these patients to know which RBS procedures to recommend to their patients, not least because there are no guidelines for choosing RBS [7].

As defined by the American Society for Metabolic and Bariatric Surgery (ASMBS) Revision Task Force, RBS includes conversion (procedures that change from one initial procedure to a different type), correction (procedures that address complications), and reversal (procedures that restore the original anatomy) [10].

RBS results in higher mortality and complication rates than primary procedures [5,6,11]. However, the literature reports an increasing trend in the percentage of "conversion" intent revision surgeries for IWL or WR based on self-referencing surgical center choices, in the absence of solid outcome data [3]. There is a lack of Italian data documenting the trend of RBS in the last 5 years (% of interventions for high-volume centers), the indications for "conversion", types of intervention and, above all, data on mortality and postoperative complications, essential for the informed consent offered to the patient candidate to RBS.

PRIMARY AIM: To analyze the trend, mortality, and complications at 30 days. SECONDARY AIMS: 30-day readmission rate, reoperations for any reason related to bariatric surgery.

Study's design: longitudinal, prospective, multicenter study. Time interval: 10 months (1 month of preparation and enrollment October 2021, 6 months of treatment November 2022 - April 2022, 1 month of follow-up May 2022, 4 months of data collection and analysis, manuscript preparation and publication May - July 2022).

Location: 11 high-volume bariatric centers of the Italian National Health Service (SSN), university hospitals, hospitals, accredited private centers.

METHODS: All bariatric revisional cases operated from 01.11.2021 - 31.04.2022 will be collected in a prospective, online database, within a dedicated website. Will be analyzed: indications; revision technique; mortality; intraoperative complications; perioperative complications; readmission to the hospital after discharge, for any reason.

All participating centers will follow the usual preoperative work-up protocol, surgical indication, informed consent, preparation for surgery and postoperative follow-up. No insurance is needed for this study, as it is an observation of routine clinical practice.

The patients operated on during the 2016-2020 period, in the same semester (November-April) will be considered as a comparative group (control group).

The prospective observational study will not involve any modification of the protocols in use in the individual centers.

Statistical analysis: categorical data will be described by absolute and relative frequency, continuous data by mean, standard deviation, and range. To make qualitative quantitative comparison regarding clinical and anthropometric factors between the two study groups (2021-22; 2016-20), the z-test for two proportions and t-test (two-tailed) will be used, respectively. The significance is fixed at 0.05 and all analyzes will be performed with the SPSS v.27 software. An online platform dedicated to the study for data entry will be used, as per the data collection form (CRF).

The study will be conducted in accordance with the principles of Good Clinical Practice, as well as with the study's protocol under registration within clinicaltrials.gov.

EXPECTED RESULTS: to enroll about 500 patients to obtain information on the safety of RBS and the current trend in Italy. DISCLOSURES: No funding is required or needed for this study. Researchers have nothing to reveal.

Study Type

Observational

Enrollment (Anticipated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Bergamo, Italy, 24040
        • Recruiting
        • Policlinico San Marco, Istituti Ospedalieri Bergamaschi, GSD
        • Contact:
      • Bergamo, Italy, 24046
        • Recruiting
        • UO Chirurgia Generale, Policlinico San Marco, Istituti Ospedalieri Bergamaschi, GSD
        • Contact:
      • Bologna, Italy, 40126
        • Recruiting
        • Unita di Chirurgia dell'Obesità e Metabolica, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Centre for the Study and Research of Treatment for Morbid Obesity, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna,
        • Contact:
      • Catania, Italy, 95122
        • Recruiting
        • UOC di Chirurgia Generale e d'Urgenza, Presidio Ospedaliero ARNAS Garibaldi Nesima
        • Contact:
      • Milano, Italy, 20089
      • Pisa, Italy, 56126
        • Recruiting
        • UOC di Chirurgia Bariatrica e Metabolica, Azienda Ospedaliera Universitaria Pisana, Presidio Ospedaliero "Nuovo Santa Chiara"
        • Contact:
      • Roma, Italy, 00165
        • Recruiting
        • UOC Chirurgia Bariatrica e Metabolica, Ospedale San Carlo di Nancy e Universita ''Tor Vergata" di Roma
        • Contact:
      • Torino, Italy, 10126
        • Recruiting
        • Dipartimento di Scienze Chirurgiche, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Università di Torino
        • Contact:
    • Basilicata
      • Potenza, Basilicata, Italy, 85050
        • Recruiting
        • UOC Chirurgia Generale, Ospedale Villa d'Agri
        • Contact:
    • LT
      • Latina, LT, Italy, 04100
        • Recruiting
        • University La Sapienza of Rome, Department of Medico-Surgical Sciences and Biotechnologies
    • Veneto
      • Padova, Veneto, Italy, 35128
        • Recruiting
        • UOSD Week Surgery, Chirurgia Bariatrica, Azienda Ospedale-Università di Padova
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Group A: all consecutive patients undergoing RBS between November 2021 - April 2022 in all involved centers; Group B (control): all patients operated on for RBS during the 2016-2020 period, in the same semester (November - April) in all involved centers will be considered as a comparative group.

All data will be collected anonymously, on a prospective, online database, with a dedicated website. Each centre will have its own slot for data submission like anthropometrics and date of primary BS, weight loss evolution, and reasons, date and anthropometrics for RBS, as well as 30-day postoperative evolution. The prospective observational study will not involve any major modification of the already established protocols, in use in each individual centers.

Description

Inclusion Criteria:

  1. Previous bariatric surgery;
  2. Age:> 18 <65 years;
  3. Compensated comorbidities;
  4. Official surgical informed consent with Covid-19 addendum in case the state of emergency continues.
  5. Revisional bariatric procedures approved by: SICOB (Italian Society of Obesity Surgery), EAES (European Association for Endoscopic Surgery) and IFSO (International Federation for Obesity Surgery), including: Roux-en-Y gastric bypass, sleeve gastrectomy or repeated sleeve gastrectomy, biliopancreatic diversion, duodenal switch, duodenal-jejunal bypass, one-anastomosis gastric bypass, single anastomosis duodeno-ileal bypass (SAID), performed exclusively laparoscopically.

Routine performance expected during the clinical study, as inclusion criteria:

  • obtaining the informed consent for participating in the clinical study;
  • delivery of the privacy, information and data treatment forms;
  • online data collection form's compilation (CRF);
  • collection of specific Italian Society of Obesity Surgery (SICOB) informed consent for revisional bariatric surgery, COVID-19 regional questionnaire and SICOB's addendum for bariatric surgery during COVID-19 (attachment 6);
  • emission of patients' letter of discharge, indicating the telephone interview after 7 and 15 days and the first outpatient check-up after 30 days;
  • information letter for the general practitioner (see attachment 7);

Exclusion Criteria:

  • no compliance to the inclusion criteria;
  • other revisional bariatric procedures than ones approved;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1. UOC Chirurgia Bariatrica, Policlinico San Marco, Zingonia, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
2. UOC di Chirurgia Bariatrica e Metabolica, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
3. UOSD Week Surgery, Chirurgia Bariatrica, Azienda Ospedale-Università di Padova, Padova, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
4. Unita di Chirurgia dell'Obesità e Metabolica, Azienda Ospedaliero-Universitaria, Bologna, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
5. UO Chirurgia Generale, Policlinico San Marco di Zingonia, Zingonia, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
6. UOC Chirurgia Bariatrica e Metabolica, Ospedale San Carlo di Nancy , Roma, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
7. Dipartimento di Scienze Chirurgiche, Azienda Ospedaliera Universitaria, Torino, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
8. UO di Chirurgia Bariatrica, Humanitas Research Hospital, Rozzano, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
9. UOC Chirurgia Generale & Bariatric Center of Excellence IFSO-EC, Latina, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
10. UOC Chirurgia Generale, Ospedale Villa d'Agri, Potenza, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement
11. UOC di Chirurgia Generale e d'Urgenza, Presidio Ospedaliero ARNAS, Catania, Italy
All patients undergoing revisional bariatric surgery in this center from 01.11.2021 through 31.04.2022 will be enrolled in a prospective, online database, registering reasons for surgery, technique, mortality, intraoperative and perioperative complications, readmission for any reason, following the same preoperative work-up protocol, indications, informed consent, and postoperative follow-up, including scheduled telephone and outpatient visits after 7, 15 and 30 postoperative days.
Any procedure performed as a second or third after an initial, primary bariatric surgery, performed due to complications or due to scarce results in term of weight loss and comorbidities improvement

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: first 30 postoperative days
Mortality after revisional bariatric surgery
first 30 postoperative days
Complications
Time Frame: first 30 postoperative days
complications after revisional bariatric surgery
first 30 postoperative days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Readmission
Time Frame: first 30 postoperative days
readmission after revisional bariatric surgery
first 30 postoperative days
Reoperations
Time Frame: first 30 postoperative days
reoperations for any reason related to revisional bariatric surgery.
first 30 postoperative days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gianfranco Silecchia, MD, PhD, Sapienza University of Rome, Italy

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

November 1, 2021

Primary Completion (ANTICIPATED)

June 30, 2022

Study Completion (ANTICIPATED)

August 31, 2022

Study Registration Dates

First Submitted

January 5, 2022

First Submitted That Met QC Criteria

January 5, 2022

First Posted (ACTUAL)

January 18, 2022

Study Record Updates

Last Update Posted (ACTUAL)

January 18, 2022

Last Update Submitted That Met QC Criteria

January 5, 2022

Last Verified

January 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity, Morbid

Clinical Trials on revisional bariatric surgical procedures

Subscribe